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To define the extent of sequence conservation in human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) in vivo, the first 320 amino acids of RT obtained from 2,236 plasma-derived samples from
a well-defined cohort of 1,704 HIV-1-infected individuals (457 drug naı¨ve and 1,247 drug treated) were analyzed
and examined in structural terms. In naı¨ve patients, 233 out of these 320 residues (73%) were conserved (<1%
variability). The majority of invariant amino acids clustered into defined regions comprising between 5 and 29
consecutive residues. Of the nine longest invariant regions identified, some contained residues and domains
critical for enzyme stability and function. In patients treated with RT inhibitors, despite profound drug
pressure and the appearance of mutations primarily associated with resistance, 202 amino acids (63%)
remained highly conserved and appeared mostly distributed in regions of variable length. This finding suggests
that participation of consecutive residues in structural domains is strictly required for cooperative functions
and sustainability of HIV-1 RT activity. Besides confirming the conservation of amino acids that are already
known to be important for catalytic activity, stability of the heterodimer interface, and/or primer/template
binding, the other 62 new invariable residues are now identified and mapped onto the three-dimensional
structure of the enzyme. This new knowledge could be of help in the structure-based design of novel resistance-
evading drugs.
The activity of the human immunodeficiency virus type 1
(HIV-1) reverse transcriptase (RT), essential for viral replica-
tion, is specifically required for the conversion of single-
stranded genomic RNA into double-stranded viral DNA,
which is later integrated into the host genomic DNA (25). For
this reason, HIV-1 RT inhibitors (RTIs) are powerful inhibi-
tors of HIV-1 replication and represent an important class of
antiretroviral agents (16).
HIV-1 RT is a multifunctional enzyme that possesses RNA-
dependent and DNA-dependent DNA polymerase activities as
well as an RNase H activity that specifically degrades the RNA
strand of RNA/DNA hybrids (25). Its structure is a het-
erodimer consisting of two subunits, termed p66 and p51. Al-
though both subunits share the first 440 amino acids (aa) of the
RT gene, their relative arrangements are significantly different,
and the substrate-binding site is located only in the p66 sub-
unit. p51 does not directly contribute to catalytic enzyme ac-
tivities (25, 38) but is essential for loading the p66 subunit on
the template/primer (27). Indeed, the single p66 monomer is
devoid of any catalytic activity.
As an intrinsic property, and in contrast to other DNA
polymerases, HIV-1 RT lacks a proofreading function. This
error-prone nature of RT, together with the high rate of virus
production sustained by HIV-1 infection in vivo, highly con-
tributes to the continuous generation of new viral variants (14,
48, 63). In addition, retroviral particles contain two copies of
single-stranded RNA, and template switches occur frequently
during reverse transcription, thus generating mutations and
recombinations by intramolecular and intermolecular jumps.
This intrinsic variability is dramatically enhanced under sub-
optimal drug pressure, resulting in mutations particularly in
the pol region encoding both RT and protease (PR) enzymes
(13, 24, 35, 65).
The emergence of resistance is the inevitable consequence
of incomplete suppression of HIV replication by the antiret-
roviral drugs and represents a frequent and major limitation of
antiviral therapy (13, 55). As a consequence, sequencing of
HIV-1 RT and PR has been recommended to guide the choice
of antiretroviral therapy in clinical practice (17, 29). Most of
the known RT inhibitor resistance mutations are in the 5
polymerase coding regions, particularly in the fingers and palm
subdomains. Therefore, on a routine basis, only the first part of
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the genetic information of RT (up to 240 to 300 aa) is generally
analyzed (57).
To date, mutations at 61 residues in the RT gene have been
related to treatment with experimentally tested RTIs (13, 24,
35, 55, 57). Of these, 18 sites are involved in resistance against
the eight currently approved nucleoside and nucleotide RT
inhibitors (NRTIs) and 16 sites are involved in resistance
against the three currently approved nonnucleoside RT inhib-
itors (NNRTIs) (35) (Stanford HIV sequence database 2005
[http://hivdb.Stanford.edu]). This variability has been exten-
sively studied (1, 6, 15, 19, 23, 24, 26, 30, 39, 46, 51, 52, 61, 67),
yet limited information is available regarding the conserved
regions of HIV RT (3, 34), even under strong antiviral pres-
sure.
The identification of conserved regions within the HIV-1
genome allows a better characterization of essential regions in
the viral proteins and can help in the design of new therapeutic
strategies aimed to drive the virus to mutate at key amino acids
that are crucial for the maintenance of sufficient viral fitness
(54). The resulting virus may be replicating at such a limited
rate that its ability to damage the immune system, and to
further mutate to compensate for such decreased fitness, is
minimal. The characterization of the conserved areas of HIV
enzymes and proteins is therefore of crucial importance to
investigate new and innovative attempts to control and prevent
efficient virus spread in the body.
This research approach led us to investigate and define the
conserved areas of HIV-1 PR (10). We then concentrated our
attention on HIV-1 RT, in an attempt to define the minimal
conserved structure of the first 320 aa of 2,236 HIV-1 RT
sequences obtained from a well-defined cohort of 1,704 HIV-
1-infected individuals (drug-naı¨ve and drug-treated patients).
Conserved amino acids have been analyzed and mapped onto
the structure of both p66 and p51 subunits using available
X-ray information. The identification of novel HIV-1 RT in-
variant regions can now be used in the rational design of new
HIV-1 RT inhibitors with a much more favorable resistance
profile.
MATERIALS AND METHODS
Patients. The study included 2,236 sequences derived from 1,704 individuals
infected with HIV-1 enrolled between 1998 and 2003 in the Italian Cohort of
Antiretroviral Naı¨ve patients or at different clinical centers in central Italy. Of
these, 457 were naı¨ve for antiretroviral drugs, and 1,247 were failing antiretro-
viral therapy regimens. Overall, drug-treated patients were experiencing a me-
dian of three highly active antiretroviral therapy regimens: 324 patients had been
treated with two RTIs, 317 patients with three RTIs, 353 patients with four RTIs,
and 778 patients with five or more RTIs; 100% of treated patients experienced
at least one NRTI, 58.2% at least one NNRTI, and 86% at least one protease
inhibitor (PI). Among NRTIs received, lamivudine was used in 91.3% of pa-
tients, zidovudine in 81.1%, stavudine in 77.3%, didanosine in 63.6%, abacavir in
21.2%, dideoxycytosine in 17.9%, and tenofovir in 2.1%; among NNRTIs, nevi-
rapine was used in 36.3%, efavirenz in 31%, and delavirdin in 0.1% of the cases.
At the time of genotypic analysis, 99% of drug-treated patients were under
treatment with NRTIs: 62.3% of patients were treated with lamivudine (median
time, 582 days), 54.4% with stavudine (median time, 553 days), 35.8% with
didanosine (median time, 432 days), 30.5% with zidovudine (median time, 577
days), 14.4% with abacavir (median time, 351 days), 2.6% with dideoxycytosine
(median time, 457 days), and 1.7% with tenofovir (median time, 171 days).
Among these RTI-treated patients, 35% were also under NNRTIs: 17.9% with
nevirapine (median time, 470 days) and 17.1% with efavirenz (median time, 448
days). PR inhibitors were included in the last regimen in 1,103 patients (62%).
HIV sequencing. HIV genotyping was performed on plasma samples by means
of a commercially available kit (the ViroSeq HIV-1 genotyping system; Celera
Diagnostics/Abbott Molecular Diagnostics, Rome, Italy) based on RNA extrac-
tion, retrotranscription, DNA amplification, and sequencing by an automated
sequencer (ABI 3100; Applied Biosystems, Foster City, CA) (10, 47). The am-
plified product contained the entire PR (99-aa) open reading frame and the first
320 aa of the RT open reading frame.
Sequence data were analyzed by dedicated HIV genotyping system software
that automatically assembles the seven sequence segments into a consensus
sequence, which is then compared to an NL4.3 reference strain. For each indi-
vidual, the quality endpoint was ensured by a coverage of the RT sequence by at
least three sequence segments. Sequences having a mixture of wild-type and
mutant residues at single positions were considered to have a mutation at that
position. When the mixture contained two different mutations, both were con-
sidered and reported (see Fig. 2). HIV subtype analysis showed that 18 out of 457
(3.9%) drug-naı¨ve patients carried non-clade B pol subtypes (F  4, A  2, C 
1, G 1, and recombinant subtypes 10). Similarly, 60 out of 1,247 RTI-treated
patients (4.8%) carried non-clade B pol subtypes (F  27, C  11, G  4, A 
4, D  2, and recombinant subtypes  12). Overall, the large majority of the
sequences included in this analysis (2,102/2,236, 94%) carried a pol B subtype
virus.
PR and RT genotypic mutations of HIV from each patient were recorded in
an anonymous database that includes demographic, immunologic, virologic, and
therapeutic parameters. The majority of nucleotide sequences from drug-naı¨ve
patients have been submitted previously to GenBank (47); see below for the
accession numbers of the new sequences.
Published pol consensus sequences of pure HIV-1 subtypes (A, B, C, D, F1,
F2, G, H, J, and K) (Los Alamos DB, http://hiv-web.lanl.gov/content/hiv-db
/mainpage.html), together with GenBank (http://www.ncbi.nlm.nih.gov)-pub-
lished pol lentiviral sequences (of HIV-2 P18042, visna/maedi virus AAM51650,
feline immunodeficiency virus [FIV] AAM13444, equine infectious anemia virus
[EIAV] AAK21112, caprine arthritis encephalitis virus [CAEV] AAG48629,
ovine lentivirus AAO33139, puma lentivirus AAA67168, simian immunodefi-
ciency virus [SIV] SIVS4 P12502 and SIVCZ P17283, and bovine leukemia virus
[BLV] P19561), were examined in this study and aligned using the Clustal X
sequence alignment program.
Mutations. Consensus B was used as a reference strain for the definition of
mutations. Mutations associated (by in vitro and in vivo studies) with resistance
to NRTIs and NNRTIs currently discovered (24, 35, 55), as well as mutations not
yet associated with drug resistance, were analyzed. In particular, the frequency of
mutations in the first 320 aa of RT was calculated and statistically compared
using the 2 test (based on a 2-by-2 contingency table containing the numbers of
isolates from untreated and treated persons and the number of isolates with and
without mutations).
Amino acids not mutated or mutated with 1% prevalence over each cohort
of patients (drug naı¨ve or treated) were defined as conserved. HIV-1 RT depic-
tions were colored according to mutation frequency rate, so that in specific
figures blue corresponds to highly conserved residues (variability in 1% of
patients), cyan to amino acids mutated only in 1 to 5% of patients, green to
amino acids mutated in 5 to 10% of patients, yellow to amino acids mutated in
10 to 25% of patients, and red to residues that appear mutated in 25% of
patients (for further details, see figure legends).
Conservative (strongly or weakly) and nonconservative amino acid substitu-
tions were recognized according to the ClustalW formalism (http://www.ebi
.ac.uk). Residue substitutions were considered strongly conservative if amino
acid alterations were from/to one of the amino acids within the following groups
having similar biochemical characteristics: STA, NEQK, NHQK, NDEQ,
QHRK, MILV, MILF, HY, and FYW; they were weakly conservative if alter-
ations were from/to one of the amino acids within the following groups having
different biochemical characteristics: CSA, ATV, SAG, STNK, STPA, SGND,
SNDEQK, NDEQHK, NEHQRK, MILVF, and HFY.
Structural analysis. Several X-ray crystallographic structures of HIV-1 RT
available from http://www.rcsb.org/pdb were used to map mutations and con-
served residues in three dimensions, namely, HIV-1 RT in complex with efa-
virenz and solved at 2.5-Å resolution (PDB code 1FK9 [49]), the apoenzyme
solved at 2.7-Å resolution (PDB code 1DLO [31]), and DNA-bound HIV-1 RT
(PDB code 1RTD [32]). The public domain program ViewerLite 5.0 (Accelrys)
was employed for visualization and display.
Nucleotide sequence accession numbers. Nucleotide sequences of isolates
from patients treated with at least a PI within the highly active antiretroviral
therapy regimens (10, 58) were recently submitted to GenBank with these ac-
cession numbers: AY855351 to AY855439, AY855441 to AY855458, AY855460
to AY855502, AY855504 to AY855556, AY855558 to AY855773, AY855775 to
AY855795, AY855797 to AY855818, AY855820 to AY855836, and AY995408 to
AY995555; the rest of the sequences are in the process of being submitted.
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RESULTS AND DISCUSSION
Degree of HIV-1 RT conservation. HIV-1 RT conservation
in vivo, both in the absence and in the presence of antiviral
pressure, was assessed by evaluating the first 320 aa of the
HIV-1 RT in 457 pol sequences of drug-naı¨ve patients and in
1,779 sequences of 1,247 RTI-treated patients. This compara-
tive analysis allowed us to observe that HIV-1 RT in vivo
requires the full preservation of at least two-thirds of its amino
acids (some with still-unknown functions), and of large areas of
its tertiary structure, to maintain a stable and functional en-
zyme.
(i) Drug-naı¨ve patients. The analysis of sequences from
drug-naı¨ve patients showed conservation (1% variability) in
233 out of 320 aa (73% overall conservation) (Fig. 1). A few
invariant residues were scattered throughout the sequence ei-
ther individually (K103, S105, N175, K201, E203, L282, G285,
K287, and L295) or either pairs or triplets, whereas the ma-
jority (159/233, 68%) clustered into 14 regions comprising 5 to
29 consecutive invariant residues (Fig. 1). The nine longest
invariant regions, containing some functionally important res-
idues, were I (T7 to P19), II (K70 to K82), III (Q91 to P97), IV
(T107 to S117, including the catalytic D110), V (F124 to S134),
VI (N147 to P157), VII (Y181 to E194, including the catalytic
D185 and D186), VIII (T216 to I244), and IX (W252 to Y271).
(ii) Drug-treated patients. In RTI-treated patients, despite
the increased appearance of mutations associated with drug
treatment, amino acid invariance was still highly maintained in
202 out of 320 aa (63% of conservation versus 73% in naı¨ve
patients, P  0.278). The majority (178/202, 88%) of these
invariant residues clustered in pairs or triplets or in regions
with more than four (up to 20) neighboring residues (Fig. 1),
confirming that participation of contiguous residues in struc-
tural domains is optimally required for cooperative function
and sustainability of enzyme activity. However, residues that
clustered in regions comprising more than five consecutive
invariant residues were strongly reduced (107/202, 53% versus
68% in drug-naı¨ve isolates, P  0.002), and the number of
single invariant residues in the group of RTI-treated patients
was increased (from 2.8% to 7.5%; P  0.018).
Compared to the nine large conserved areas found in drug-
naı¨ve patients, the degree of conservation in drug-treated pa-
tients was almost identical at six regions (I, III, IV, V, VI, and
IX). Minor exceptions were found at T7, K11, and F116 (with
a variation frequency somewhat increased to 3% of patients)
and V108 and Q151 (with a variation frequency increased up
to 6% and 4% of patients, respectively). Interestingly, the
decrease of variation of aa 146 (from 2 to 0.8%) that was found
in the group of RTI-treated patients resulted in an upstream
extension of conserved area VI up to position R143.
By contrast, a different picture, characterized by a substan-
tial decrease of amino acid conservation, was observed in the
other three large conserved areas (II, VII, and VIII). The
conserved areas II and VII markedly shrank to smaller
stretches, whereas the largest conserved region, VIII, was split
into several isolated conserved residues and two smaller con-
served areas (229 to 237 and 239 to 244) (Fig. 1).
These results are consistent with a previous analysis con-
ducted on 1,210 different RT sequences from drug-naı¨ve and
NRTI-treated (but NNRTI-naı¨ve) individuals (24). However,
this study addressed only the mutation frequency at RT posi-
tions 1 to 240; in addition, the focus was on characterizing RT
mutations, while distinction between invariant residues (vari-
ability of 1%) and residues with low variability (3%) was
not made. Taking into account these considerations and de-
spite a general agreement, differences with that analysis were
found in the rate of conservation at a small number of amino
acid positions (e.g., 36, 88, 172, and 175 and obviously NNRTI-
associated residues [100, 181, 189, 190, 194, 225, and 227]) for
which we found variability of 1% (and 5% at residues 181
and 190), not reported in the aforementioned study (24), and
at residues 111, 115, 224, and 239, for which variability was
reported to be 3% in NRTI-treated patients (1% in our
study). It is assumable that the differences in RT conservation/
mutation patterns highlighted by these studies may reflect the
circulation of distinct viruses in different geographic areas as
well as variation in patients’ characteristics and RTI regimens.
Pattern of HIV-1 RT mutations. We found several RT poly-
morphisms in drug-naı¨ve patients. Among 87 variable residues,
42 were mutated in 5% of drug-naı¨ve patients; of them, 14
were highly variable (replaced in 25%) (Fig. 1). The fre-
quency of the major drug resistance mutations in drug-naı¨ve
patients was consistently 1%, with only the exception of
V118I (2.6%), while minor drug resistance mutations (or un-
known mutations in drug resistance-associated residues) were
present at low variability in drug-naı¨ve patients: A98S (6.8%),
K101R (2.2%), V106I (1.3%), E138A (3.5%), V179I (3%),
and T215D (1.8%) (Fig. 2).
As expected, the development of drug resistance during
therapy failure resulted in a general increase of mutations in
the RT from RTI-treated patients, with 70 out of 320 residues
(22%) found mutated in 5% of patients (compared to 42 in
drug-naı¨ve patients [13%], P 0.005). Of these, 20 were highly
variable (replaced in 25%) (Fig. 1).
Statistically significant differences (P 0.05 by 2 test) in the
variability frequency between HIV-1 RT sequences from drug-
naı¨ve and RTI-treated patients were found at 53 out of 320
residues (17%) (shown in boldface type in Fig. 2). Among
them, 17 known NRTI resistance sites (M41, E44, A62, K65,
D67, T69, K70, L74, V75, F77, F116, V118, Q151, M184, L210,
T215, and K219) and 16 known NNRTI resistance sites, not
only for efavirenz and nevirapine (A98, L100, K101, K103,
V106, V108, I135, E138, V179, Y181, Y188, V189, G190, P225,
F227, and K238), were identified (35, 55, 57; http://hivdb.Stan-
ford.edu). Besides, seven new sites (E28, K122, G196, Q278,
R284, T286, and A288) were positively associated with RTI
treatment, together with nine sites (K20, T39, K43, E203,
H208, D218, H221, K223, and L228) recently associated with
NRTI therapy (24). Interestingly, at four new sites (T27, I50,
R83, and V276) the variability frequency was statistically de-
creased in the group of RTI-treated patients relative to the
group of drug-naı¨ve patients (P  0.004; Fig. 2).
Regarding the type of mutations, some unusual changes at
known NRTI resistance sites (less common than others at the
same positions) (E44A, D67G, L74I, V75M, V75T, T215I,
K219R, and K219N), as well as novel mutations not yet asso-
ciated with resistance to any known RTI (K20R, E28A, E28K,
V35M, T39A, K43E, K43Q, K43N, K122E, G196E, E203K,
E203D, H208Y, D218E, H221Y, K223Q, K223E, L228H,
L228R, Q278H, R284K, T286A, and A288T), were signifi-
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FIG. 1. Conserved regions of HIV-1 RT in drug-naı¨ve and drug-treated HIV-1-infected patients. The sequence of the first 320 aa of HIV-1 RT
of clade B consensus (shown as a reference) is colored according to the frequency rate of mutations observed in 457 plasma samples from
drug-naı¨ve patients and 1,779 plasma samples from RTI-treated patients. The long invariant regions are boxed (I to IX) in both drug-naı¨ve and
RTI-treated patients.
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FIG. 2. Polymorphisms and mutations in HIV-1 RT from drug-naı¨ve and RTI-treated patients. Amino acid mutations in HIV-1 RT from 457
plasma samples from drug-naı¨ve patients and 1,779 samples from RTI-treated patients are reported. The clade B consensus sequence is shown as
a reference. Residues associated with RTI treatment by previous in vitro or in vivo studies (24, 35, 55, 56) are underlined. Residues whose wild-type
prevalence differs significantly (P  0.05) between naı¨ve and treated patients are shown in boldface. The predominant mutation for each position




cantly increased in treated patients (P 0.05 to 0.0001).
Surprisingly, a few positions were characterized by a decreased
rate of mutations in treated versus drug-naı¨ve patients: T27P
(from 1.3 to 0.22%, P  0.007), T27A (from 1.3 to 0.11%, P 
0.001), V35I (from 20.8 to 11.3%, P 0.0001), I50V (from 5 to
2.3%, P  0.004), R83K (from 33 to 18.6%, P  0.0001), and
V276I (from 5 to 1.7%, P  0.0001).
Interestingly, among mutations not yet associated with re-
sistance to any known RTI, some of them (T39A, K122E, and
T286A) were also included as candidate mutations for drug
resistance and positive reproductive fitness, by having a ratio of
nonsynonymous mutations to synonymous mutations (Ka/Ks)
of 1, with values similar to those observed for the already-
known RTI resistance mutations (12).
Structural interpretation of the minimal conserved areas of
HIV-1 RT. It is known that the HIV-1 RT catalytic activities
are localized in the p66 subunit that is composed of all 560 aa
encoded in the RT gene, whereas the p51 subunit, made up of
440 shared aa, displays no enzymatic activity although it pro-
vides essential structural support to the enzymatically active
p66 monomer in the RT dimer (25). It is important to recall
that the shared 440 aa are arranged in structurally different
ways in p66 and p51 and also that mutations occurring in vivo
in the RT genome influence both subunits (50). Therefore, in
an attempt to define an improved minimal conserved structure
of HIV-1 RT, we rationalize our findings also in structural
terms by mapping the first 320 aa of RT from both naı¨ve and
treated patients onto a three-dimensional representation of
both p66 and p51 subunits (Fig. 3). Among the large conserved
areas observed in drug-naı¨ve patients, regions I (7 to 19), II (70
to 82), and V (124 to 134) are located in the “fingers” subdo-
main (1 to 88 and 121 to 146). Regions III (91 to 97), IV (107
to 117), VI (147 to 157), VII (181 to 194), and VIII (216 to 244)
are located in the “palm” subdomain (89 to 120 and 147 to
242), while region IX (252 to 271), containing a long -helix,
usually termed H, is in the “thumb” subdomain (243 to 311)
(Fig. 3). The IV and the VII areas contain, respectively, the
three aspartate residues involved in catalysis (D110, D185, and
D186). The largest conserved area in drug-naı¨ve patients, VIII
(216 to 244), contains residues (224 to 235) that are involved in
positioning the primer terminus (“primer grip” [40]).
Several known mutations associated with RTI treatment
and/or RTI resistance (at residues K219, H221, K223, P225,
F227, L228, and K238) appeared in the VIII area, whereas the
-stranded stretch 229 to 237 and residues 224, 226, and 239 to
244 remained fully conserved (Fig. 4). The fact that in this
region some residues that also line the NNRTI binding pocket
(W229, E233, L234, and P236) are not mutated suggests that
the primer grip residues have critical architectural and func-
tional roles.
A “template grip” has also been described in the fingers
subdomain (residues 67 to 83) and in the palm (residues 86 to
93 and 148 to 154) that interacts with the DNA sugar-phos-
phate backbone of the template strand (9, 32, 33, 60). In naı¨ve
patients, with the exception of D67, S68, T69, and V90 (vari-
ability of5%) and R83 (variability of 33%), all these residues
are conserved and some are clustered in conserved regions (II
and VI). In drug-treated patients, many NRTI resistance mu-
tations fall into these areas (K65R, D67N, T69D, K70R, L74V,
V75I, F77L, and Q151M), whereas residues 66, 71 to 73, 76,
the B 78 to 82, 86 and 87, 89, 91 to 93, 147 to 150, and 152 to
154 remain conserved. It is interesting that, from mutational
FIG. 3. HIV-1 RT conserved area locations. Left: Ribbon representation of the C trace of HIV-1 RT (as found in the X-ray crystal structure
with PDB code 1DLO) with p66 and p51 subunits each enveloped by a solvent-accessible surface colored in blue and pink, respectively. The boxed
area is enlarged in Fig. 4. Right: Ribbon representation of the X-ray crystal structure of HIV-1 RT showing the location in both p66 and p51
subunits of the large conserved areas (I to IX) characterized in both drug-naı¨ve and RTI-treated patients.
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analyses of the 67 to 81 region, residues W71, R72, D76, R78,
and N81 (residues also evolutionarily conserved) were intoler-
ant of substitution compared to the other nine, thus suggesting
an important role for these residues in polymerase activity (8,
37).
Region IX (252 to 271) is the largest of all the fully con-
served stretches in both naı¨ve and drug-treated patients (Fig. 1
and 3). Residues 259 to 284 exhibit sequence homology with
other nucleic acid polymerases and have been termed the “he-
lix clamp” (4, 28). In p66 these residues belong to the poly-
merase domain as part of the thumb, and it has been shown by
alanine-scanning mutagenesis that specific amino acids (Q258,
G262, and W266) are critical for template-primer affinity (5).
Another recent paper has demonstrated that mutation of N255
or N265, each adjoining the minor groove-binding track, to
aspartate leads, respectively, to a drastic reduction of proces-
sive synthesis on both templates or to a loss of processive
polymerization on DNA but not on RNA (18). The invariant
region IX in the p66 subunit is essential for DNA polymeriza-
tion and can have an important role also in p51. In fact, 	
(V254 to S268) in the p51 subunit is in contact with the RNase
H domain of p66, suggesting a substantial contribution of this
region to dimer stabilization (38, 41, 62).
In this regard, the segment from I135 to P140 in p51, which
is part of the 7-8 loop and essential for the catalytic activity
of the p66 subunit, has been identified as a “hot spot” of
binding energy (53) and is invariant in HIV-1 RT in three
residues, N136, N137, and P140. In particular, N136 represents
a highly conserved amino acid among all known lentivirus RTs,
whose role in HIV-1 RT has been recently shown to be se-
verely compromised upon mutation to other amino acids (2a).
The NNRTI binds at a hydrophobic pocket approximately
10 Å from the polymerase active site (38). Analyzing the con-
servation within the NNRTI binding pocket, in drug-naı¨ve
patients, 14 of 19 residues that make up the hydrophobic
NNRTI binding pocket (P95, L100, K103, V108, Y181, Y183,
Y188, G190, P225, F227, W229, E233, L234, and P236) are
fully conserved (1%), others (K101, V106, and Y318) are
mutated at low frequency (3%), and two (A98 and V179) are
mutated in 5 to 8% of patients (Fig. 4). As expected, and in
contrast to what is observed in naı¨ve patients, the NNRTI
binding cavity of HIV-1 RT from drug-experienced individuals
displays a high and variable occurrence (from 5 to 29%) of
mutations at positions A98, K101, K103, V106, V108, V179,
Y181, and G190. Nevertheless, seven residues (P95, Y183,
W229, E233, L234, P236, and Y318) remain fully conserved,
and others (L100, Y188, P225, and F227) are mutated only
rarely (4% frequency) (Fig. 4). The invariant amino acids in
the HIV-1 NNRTI binding pocket, as already shown for W229
and Y318 (44, 45), should be regarded as prime candidates to
be targeted by modified or novel NNRTIs (43) in order to
rationally design new drugs with a more favorable resistance
profile.
RT evolutionary conservation. Being aware of the potential
limitation of working solely with HIV-1-derived data (mainly B
subtype), we undertook an analysis of RT conservation also in
a variety of HIV-1 clades and other published retroviral se-
quences. Consistent with the pattern of sequence conservation
observed in HIV-1 RT from isolates of drug-naı¨ve patients, the
largest invariant regions are also highly conserved in RTs from
other HIV-1 subtypes (A, C, D, F1, F2, G, H, J, and K), with
the single exception of RT from clade H in which, at position
107, Thr (present in all subtypes) has been replaced by Ser (a
conservative mutation) (data not shown). This indicates that,
in the absence of any drug pressure and independent of both
virus origin and circulation, HIV-1 RT amino acid variations
(i.e., mutations) are indeed allowed (more than 30% of the
sequence), but only in restricted selected areas.
In contrast, when we compared the sequence of the first 320
aa of HIV-1 RT consensus clade B with the corresponding RT
sequences from other lentiviruses (HIV-1 subtypes, HIV-2,
EIAV, visna/maedi virus, CAEV, BLV, FIV, and SIV) a com-
pletely different picture (Fig. 5), characterized by a substantial
decrease of amino acid conservation, became visible. Indeed,
among all viruses only 73/320 residues were fully conserved, 47
residues mutated toward strongly conservative amino acid sub-
stitutions, and 17 residues mutated toward weakly conservative
substitutions, with an overall evolutionary conservation of 137
residues out of 320 (43%). As previously proposed (3), the N
terminus of the HIV-1 RT lies on a surface distantly located
from the active site and is accessible to the HIV-1 PR. This
area is subject to a considerable variation. Instead, the most
evolutionarily conserved RT regions (in the frame of aa 20 to
190 of HIV-1 RT) are within the inner surface of the enzyme
and responsible for polymerization function. Overall, several
evolutionarily conserved stretches in lentiviral RTs were also
found invariant in HIV-1 RT under antiviral pressure (G18-
P19, Q23 to L26, E29-K30, G45 to I47, N57 to P59, W71-R72,
R78 to K82, G93 to P97, L109 to V111, D113 to Y115, P119-
L120, Y127 to I132, N136-N137, R143-Y144, L149-P150,
G152-W153, S156-P157, I159 to Q161, I167-L168, D185 to
FIG. 4. Detail of the NNRTI binding and catalytic sites in HIV-1
RT. Enlarged view of the boxed area shown in Fig. 3. The C trace of
HIV-1 RT, as found in its crystallographic complex (PDB code 1FK9)
with efavirenz (shown as sticks), is displayed as a ribbon, colored in
gray and pink for the p66 and p51 subunits, respectively, except for all
residues having a mutation frequency of 1%, which are colored in
green. Side chains of nonmutable residues in the neighborhood of the
NNRTI binding site, together with the active-site aspartates (D185,
D186, and D110), are shown as sticks, with carbon atoms colored in
green.
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L187, S191-D192, W229 to Y232, and T253 to L260) (Fig. 5,
see boxes), whereas a lower number of RT residues are overall
conserved in more distantly related retroviral sequences (P52,
N57, P59, K65, R72, D76, R78, N81, D110, D113, F116, A129-
F130, L149 to G152, S156-P157, L168, Y183, D185-D186,
L209, G213, K220, G231, and G262) (34).
To our knowledge, among the 202 HIV-1 RT residues iden-
tified as invariant in our study, 62 have not been yet individu-
ally characterized for their function and should become the
subject of future therapeutically oriented studies (P1 to S3, I5,
V8 to V10, L12 to P19, K22 to W24, K82, T84 to F87, E89,
L205-R206, L209, W212-G213, T216-P217, K220, Q222, P236-
D237, W239 to I244, L246-P247, W252, G273-I274, T290,
L295, E298, E300, E302, A304 to I309, V314 to G316, and
Y319-D320). Some of these residues are invariant among all
other lentiviral RTs, suggesting an essential role for RT struc-
ture and/or function (G18-P19, Q23-W24, E89, G213, P217,
K220, Q222, P236, W239, Q242, and L246) (Fig. 5).
At least 140 HIV-1 RT conserved residues have been mu-
tagenized in vitro, and the effect of one or more of these
mutations has been analyzed by measuring RNA- and/or
DNA-dependent DNA polymerase activity, RNase H activity,
strand transfer, structural stability, and/or p66-p51 het-
erodimerization (2, 2a, 4, 5, 7, 8, 11, 18, 20–22, 37, 40–42, 44,
45, 59, 64). Of these 140 mutagenized residues, 79 (56%) have
been shown to be extremely important to keep the functional
and/or structural integrity of RT, thus confirming their key role
in RT and the necessity for their conservation. In contrast, the
other 61 invariant residues (44%) did not show any drastic
effects on the efficiency of in vitro RT/RNase H activity (30%
of that of wild-type HIV RT). This does not necessarily prove
an unsupportive role in HIV-1 RT structure and/or function
but suggests that these amino acids, in principle, may be mu-
tated without a deleterious loss of catalytic RT efficiency. The
fact, for instance, that the majority of these residues (48/61)
are subject to variation in the larger world of lentiviruses (3)
(Fig. 5) may confirm that substitutions on these sites are tol-
erable in vivo, without causing a major deleterious effect on the
RT enzyme. Therefore, we cannot exclude that mutations at
some of these residues may occur under the pressure of novel
FIG. 5. Conserved regions of RT in lentiviruses. The sequence of the first 320 aa of HIV-1 RT of clade B consensus (shown as a reference)
is colored according to the degree of conservation observed in different lentiviruses. Published pol consensus sequences of pure HIV-1 subtypes
(A, B, C, D, F1, F2, G, H, J, and K) together with published pol sequences of HIV-2 (P18042 from residue 198), visna virus (AAM51650 from
residue 160), FIV (AAM13444 from residue 163), EIAV (AAK21112 from residue 175), CAEV (AAG48629 from residue 147), ovine lentivirus
(AAO33139 from residue 14), puma lentivirus (AAA67168 from residue 64), SIVS4 (P12502 from residue 168), SIVCZ (P17283 from residue 180),
and BLV (P19561 from residue 157) were aligned using the Clustal X program. Mutated residues with conservative amino acid substitutions were
considered either strongly conserved, if amino acid alterations were from/to one of the amino acids within the groups STA, NEQK, NHQK,
NDEQ, QHRK, MILV, MILF, HY, and FYW, or weakly conserved, if alterations were from/to one of the amino acids within the groups CSA,
ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEHQRK, MILVF, and HFY. RT conserved regions in lentiviruses and HIV-1 (from
our cohort of drug-naı¨ve and RTI-treated patients) are boxed.
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RT inhibitors with a different mechanism of action. Future
studies may provide answers to these considerations. On the
other hand, the other residues (13/61) that are invariant also
among other lentiviruses may play a role or perform a function
that cannot be easily detected by the usual in vitro assays,
which do not always cover the multifunctional activities of
HIV-1 RT, but are possibly amenable to targeting by new
drugs. This further emphasizes the important value of both in
vivo and in vitro observations to achieve results that are both
noticeable and reliable and demonstrates that the need of
evolutionary conservation is not sufficient to avoid the problem
of RT becoming resistant to nucleoside analogues, even if they
interact with the well-conserved polymerase active site.
Finally, we should consider that the conservation or muta-
tion at the amino acid level observed in vivo is also dependent,
besides the functional or structural constraint, on the nature of
the amino acid itself, and thus the codon usage may be relevant
in the development of immune escape and drug resistance
(36). To detect the overall selection pressure at the amino acid
level of HIV-1 RT, nucleic acid sequences of 179 randomly
selected patients with clade B pol subtype were analyzed. The
ratio between nonsynonymous and synonymous substitutions
(dn/ds) was calculated as a measure of selection pressure (66).
Both RT and PR genes were under strong purifying (negative)
selection pressure (dn/ds  1) in both drug-naı¨ve and drug-
treated patients, as previously reported (12, 56). Interestingly,
RT nucleotide sequences showed a remarkably lower dn/ds
ratio than PR, suggesting a greater conservation of RT even
under drug pressure (data not shown). Recently, analyzing
40,000 samples of sequences of the entire PR and the first 381
RT codons, Chen et al. detected 69 individual PR mutations
and 142 RT mutations under positive selection pressure (12).
Among the 107/381 RT codons reported with a Ka/Ks value of
1, very few were invariant residues in our study (I31, S105,
T107, P176, P243, I257, A304, I309, and Y319).
In conclusion, HIV-1 can become resistant to the currently
available drugs because of its high replication and mutation
rate (54), yet several amino acid sequences are highly con-
served even under strong drug pressure. The data presented
here may allow the design of new drugs that force the virus
toward a mandatory escape to residues characterized by
changes in the replicative capacity extremely detrimental for its
replication. The resulting mutant virus may be replicating at a
limited rate such that its ability to damage the immune system,
as well as to further mutate to compensate for the loss of
replication capacity, would be remarkably decreased. There-
fore, the characterization of the highly conserved residues (in-
volved in protein stability, dimerization ability, template-
primer binding, or catalytic activity, and some still poorly
understood functions) could help in the rational design of new
HIV-1 inhibitors with alternative mechanisms of action and
more favorable resistance profiles.
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